Reaction inhibitor

Assembly Biosciences to Present Data from HBV Core Inhibitor Programs at The International Liver Congress™ EASL 2021

Retrieved on: 
星期三, 六月 9, 2021
European Association for the Study of the Liver, Potency, Reaction inhibitor

During the meeting, data from Assembly Bios three core inhibitor programs, vebicorvir (VBR), ABI-H2158 (2158) and ABI-H3733 (3733), will be featured in an oral presentation and two poster presentations.

Key Points: 
  • During the meeting, data from Assembly Bios three core inhibitor programs, vebicorvir (VBR), ABI-H2158 (2158) and ABI-H3733 (3733), will be featured in an oral presentation and two poster presentations.
  • Posters are expected to be made available to conference registrants through the online EASL portal at the start of the meeting on the morning of Wednesday, June 23, 2021.
  • The next-generation compounds 2158 and 3733 show enhanced potency and exposures that cover cccDNA prevention at significant multiples above protein-adjusted EC50 at Cmin.
  • Overall, most patients (78%) did not have detectable core inhibitor substitutions; for patients harboring a core inhibitor substitution (22%), no enrichment compared to baseline was observed after treatment was removed.

Precision BioLogic's CRYOcheck™ Factor VIII Inhibitor Kit Cleared for Sale in U.S.

Retrieved on: 
星期三, 三月 13, 2019
Coagulation system, Proteins, Branches of biology, Recombinant proteins, Cofactors, Factor VIII, Factor VII, Reaction inhibitor

The presence of factor VIII (FVIII) inhibitors reduces therapy effectiveness and is one of the most complex and costly complications for people with hemophilia A.

Key Points: 
  • The presence of factor VIII (FVIII) inhibitors reduces therapy effectiveness and is one of the most complex and costly complications for people with hemophilia A.
  • Precision BioLogic developed the CRYOcheckFactor VIII Inhibitor Kit to address this challenge.
  • A modified Nijmegen-Bethesda assay is used to determine FVIII inhibitor levels in people with hemophilia A.
  • According to Paul Empey, President & CEO of Precision BioLogic, FDA 510(k) clearance of the CRYOcheckFactor VIII Inhibitor Kit is an exciting milestone for the company but more importantly, a step forward for patient care.